Evidence map›Paper›PMID 42593581›Full record

ArticleAnnals of surgical oncology2026

Bright Visualization of Primary and Metastatic Medullary Thyroid Cancer in an Orthotopic Nude Mouse Model Using a Fluorescent Humanized Anti-CEA Antibody for More Accurate Staging and Improved Resection.

Javier Bravo, Sohee Lee, Blackberrie Eddins, Sunidhi Jaiswal, Siamak Amirfakhri, Grace Lin, Kristin E Cox, Thinzar M Lwin, Robert M Hoffman, Hak Soo Choi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Javier BravoDepartment of Surgery, UCSD Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.
Sohee LeeDepartment of Surgery, UCSD Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.
Blackberrie EddinsDepartment of Surgery, UCSD Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.
Sunidhi JaiswalDepartment of Surgery, UCSD Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.
Siamak AmirfakhriDepartment of Surgery, UCSD Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.
Grace LinDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Kristin E CoxDepartment of Surgery, UCSD Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.
Thinzar M LwinDepartment of Surgical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Robert M HoffmanDepartment of Surgery, UCSD Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.
Hak Soo ChoiTheranostics Convergence National Research Laboratory, Chungnam National University, Daejeon, South Korea.
Paul J YazakiDepartment of Immunology and Theranostics, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Michael BouvetDepartment of Surgery, UCSD Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA. mbouvet@ucsd.edu.ORCID http://orcid.org/0000-0002-0086-2159

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Targeting parathyroid glands with novel fluorophores for intraoperative imagingR01CA280968 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Michael Bouvet, Maged M Henary · 2023 to 2026
$2.8M
NCI NIH HHS R01CA280968NCI NIH HHS T32CA121938
6 · The paper itself

Abstract

backgroundThe standard treatment for medullary thyroid cancer (MTC) is total thyroidectomy with cervical lymph node dissection. Cure depends on complete surgical resection; however, intraoperative identification of tumor margins and involved lymph nodes remains challenging.

methodsThe CEA-expressing MTC cell line TT was used to establish orthotopic thyroid tumor models (n = 7), whereas the non-CEA-expressing papillary thyroid cancer (PTC) cell line TPC-1 was used to establish subcutaneous negative control tumor models (n = 3). Orthotopic MTC models were established by injecting TT cells (1x10

resultsThe mean TBR of orthotopic MTC tumors treated with M5A-IR800 was 6.85 (±3.75) at 96 hours post injection. Mice bearing subcutaneous TT tumors also achieved high TBRs of 4.23, 3.59, and 3.3 at 96 hours. In contrast, non-CEA-expressing TPC-1 tumors demonstrated no detectable fluorescence. Hematoxylin and eosin staining and immunohistochemistry confirmed accurate tumor targeting by M5A-IR800 and strong CEA expression in MTC tumors.

conclusionsM5A-IR800 specifically and brightly targets MTC in preclinical mouse models and represents a promising approach to enhance intraoperative visualization of MTC.

Identifiers

PMID42593581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.